Periciazine

Periciazine

Systematic (IUPAC) name
10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile
Clinical data
Pregnancy category	AU: C
Routes of administration	Oral
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) ℞ (Prescription only)
Pharmacokinetic data
Metabolism	Hepatic (mostly via conjugation)[1]
Biological half-life	12 h[1]
Excretion	Renal[1]
Identifiers
CAS Number	2622-26-6
ATC code	N05AC01 (WHO)
PubChem	CID 4747
DrugBank	DB01608
ChemSpider	4585
UNII	3405M6FD73
KEGG	D01485
ChEBI	CHEBI:31981
ChEMBL	CHEMBL251940
Chemical data
Formula	C21H23N3OS
Molar mass	365.49 g/mol
SMILES C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N
InChI InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2 Key:LUALIOATIOESLM-UHFFFAOYSA-N
(what is this?)  (verify)

Periciazine (INN), also known as pericyazine (BAN) or propericiazine, is a drug that belongs to the phenothiazine class of typical antipsychotics.

Pericyazine is not approved for sale in the United States. It is commonly sold in Canada under the tradename Neuleptil and in United Kingdom and Australia under the tradename Neulactil.^[2]

Medical Uses

The primary uses of pericyazine include in the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia. There is insufficient evidence to determine whether periciazine is more or less effective than other antipsychotics.^[1][3]

Periciazine has also been studied in the treatment of opioid dependence.^[4]

Adverse effects

Pericyazine is a rather sedating and anticholinergic antipsychotic, and despite being classed with the typical antipsychotics, its risk of extrapyramidal side effects is comparatively low.^[5] It has a relatively high risk of causing hyperprolactinaemia and a moderate risk of causing weight gain and orthostatic hypotension.^[5]

References

1. "NEULACTIL PRODUCT INFORMATION" (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. 13 September 2011. Retrieved 2 November 2013.
2. Pericyazine. Martindale: The Complete Drug Reference (The Royal Pharmaceutical Society of Great Britain). 23 September 2011. Retrieved 2 November 2013.
3. Leucht S, Helfer B, Hartung B. Perazine for schizophrenia. Cochrane Database Syst Rev. 2014 Jan 15;1:CD002832. Review. doi:10.1002/14651858.CD002832.pub3 PMID 24425538
4. Sivolap IuP, Savchenkov VA (1999). "[The use of neuroleptics in treating opiate dependence]". Zh Nevrol Psikhiatr Im S S Korsakova (in Russian) 99 (6): 29–34. PMID 10441864.
5. "Approximate relative frequency (not intensity) of common adverse effects of antipsychotics (Table 8.21) [NB1]". eTherapeutic Guidelines complete. Therapeutic Guidelines Limited. February 2013. Retrieved 2 November 2013.

External links

• Neulactil - Summary of Product Characteristics from the electronic Medicines Compendium
• from the Therapeutic Goods Administration.
• from Health Canada.